U.S. Markets closed

Seres Therapeutics, Inc. (MCRB) Shares March Higher, Can It Continue?

Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Seres Therapeutics, Inc. MCRB. The stock has moved higher by 15.2% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider MCRB’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as MCRB has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

It’s Illegal in 42 States, But Investors Will Make Billions Legally

In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year.

That’s twice as much as they spend on marijuana, legally or otherwise.

Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.

See these 5 “sin stocks” now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Seres Therapeutics, Inc. (MCRB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research